Related Experiment Video

Updated: Apr 25, 2026

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
13:08

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

19.9K

Transient cefuroxime/metronidazole treatment induced factor V antibodies

Sjoerd Adrianus Antonius Van den Berg1, Patricia E Verwer2, René N Idema1

  • 1Laboratory for Clinical Chemistry and Hematology, Amphia Ziekenhuis, Breda, Noord Brabant, The Netherlands.

BMJ Case Reports
|August 21, 2014
PubMed

Insights

Antibiotics can rarely cause transient factor V antibodies, leading to mild blood clotting issues. This case highlights a patient who recovered fully after antibiotic cessation without bleeding complications.

Area of Science:

  • Hematology
  • Clinical Medicine
  • Pharmacology

Background:

  • Appendiceal infiltrates often require antibiotic treatment.
  • Coagulopathy can be a rare complication of certain medications.
  • Factor V antibodies are an uncommon cause of bleeding disorders.

Observation:

  • A patient developed prolonged prothrombin time (PT) and activated partial thromboplastin time (aPTT) during antibiotic therapy for an appendiceal infiltrate.
  • The prolonged clotting times were unresponsive to vitamin K or prothrombin complex concentrate.
  • Laboratory findings revealed reduced factor V activity and the presence of factor V antibodies.

Findings:

  • Unlike typical cases, this patient had only mild prolongation of PT and aPTT with residual factor V activity >20%.
  • Percutaneous drainage of the abscess did not result in significant bleeding.
  • Clotting parameters normalized within a week after antibiotic treatment cessation, with factor V activity returning to 36%.

Implications:

  • This case suggests antibiotics can induce transient factor V antibodies.
  • The absence of a significant bleeding tendency in this patient offers new insights into factor V antibody-associated coagulopathy.
  • Further research is warranted to explore the mechanisms and clinical significance of antibiotic-induced factor V antibodies.

More Related Videos

Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R2029106:51

Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291

Published on: December 10, 2016

12.0K
Ferric Chloride-induced Thrombosis Mouse Model on Carotid Artery and Mesentery Vessel07:26

Ferric Chloride-induced Thrombosis Mouse Model on Carotid Artery and Mesentery Vessel

Published on: June 29, 2015

17.9K

Related Concept Videos

Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence01:22

Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence

Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...
257
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
482
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.7K
Transient Ischemic Attack l: Introduction01:26

Transient Ischemic Attack l: Introduction

A transient ischemic attack (TIA) is a brief episode of neurological dysfunction caused by a temporary, focal reduction in cerebral blood flow. Although symptoms resemble those of an ischemic stroke, the interruption in perfusion is short-lived and does not cause permanent infarction. TIAs are clinically important because they often serve as early warning events for future stroke.Mechanisms of Transient Cerebral IschemiaTransient cerebral ischemia may arise through several mechanisms. One...
13
Cytomegalovirus Disease01:27

Cytomegalovirus Disease

Cytomegalovirus (CMV) disease is caused by human cytomegalovirus, a double-stranded DNA virus of the Herpesviridae family. While primary CMV infection is often asymptomatic in immunocompetent individuals, the virus can cause severe disease in neonates and immunocompromised patients. CMV is the most common cause of congenital viral infection in the United States, and a major pathogen in solid organ and hematopoietic stem cell transplant recipients.CMV is transmitted via bodily fluids, sexual...
94
Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
428